Connect with us

Hi, what are you looking for?


Biogen Erases Gains After Analysts Raise Price Targets

Stock Markets52 minutes ago (Jun 11, 2021 10:37AM ET)

(C) Reuters.

By Dhirendra Tripathi – Biogen (NASDAQ:BIIB) shares fell close to 2% Friday despite analysts raising their price targets after the Food and Drug Administration’s decision to approve the company’s Alzheimer’s drug.

The biotech company’s aducanumab is the first Alzheimer’s medicine in 18 years to secure the FDA nod, which came Monday (NASDAQ:MNDY).

Bernstein and JPMorgan (NYSE:JPM) raised their price targets on potential sales from the drug.

Bernstein’s outperform rating sees the Biogen stock at $500, an upside of 22% from the stock’s current level of $410.

According to analyst Aaron Gal, market circumstance will allow for strong adoption of Biogen’s ‘aduhelm’ and that regulatory scrutiny of the price of the new Alzheimer’s drug will come later.

He sees aduhelm sales reaching $10 billion in 2023, with conservative assumptions.

Biogen will charge $56,000 for an annual course, a price drawing much criticism from advocacy groups.

JPMorgan analyst Cory Kasimov raised Biogen’s target price to $435 while maintaining a neutral rating.

Biogen Erases Gains After Analysts Raise Price Targets

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

World News

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered...

World News

George Soros and Bill Gates are part of a consortium acquiring a British developer of rapid-testing technology, including for Covid-19 and tropical diseases,...


If you parked your car in one of the thousands of parking spots across Calgary, there’s a good chance you paid the Calgary Parking...


ForexMay 27, 2021 02:04AM ET (C) Reuters. By Peter Nurse — The dollar edged higher in early European trade Thursday, finding support from...

Disclaimer: it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. Copyright © 2021 Your Morning Voice. All Rights Reserved